Stivarga

Home/Tag: Stivarga

The Heart of the Matter: Cardiac Health for GIST Patients

The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]

By |2019-09-20T15:37:59-04:00February 10th, 2016|GIST Education, Newsletter, Side Effects|

Regorafenib-Related Hand-Foot Skin Reaction

A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]

By |2019-10-31T13:40:24-04:00June 26th, 2015|Coping with GIST, News, Side Effects|

UK Pulls Stivarga From Cancer Drug Fund Endangering GIST Patients

The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]

By |2018-09-10T09:36:55-04:00January 29th, 2015|Advocacy, News, Stivarga|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Stivarga Approved for Canadian GIST Patients

Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]

By |2019-09-20T11:39:34-04:00October 18th, 2013|Drug Treatment, News, Stivarga|

Stivarga Approved to Treat GIST Patients in Japan

Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information.Official Stivarga Press Release:Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing of Regorafenib (Stivarga) [...]

By |2019-09-20T12:04:14-04:00August 21st, 2013|Drug Treatment, News, Stivarga|

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By |2019-09-20T13:00:30-04:00February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

Patients Face Numerous Obstacles In Quest For Life-Saving Treatment

“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.

By |2019-04-18T11:51:54-04:00February 1st, 2013|Advocacy, Coping with GIST, Drug Treatment, News|
Go to Top